spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

6th Annual Cancer Vaccines Conference

SMI - 6th annual Cancer Vaccines Conference

27-28 September 2017
Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual show will capture expert insight by honing in on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatment, immune check-point inhibitors, plus more.

Join us this September for strategic direction on vaccine commercialisation and arm yourself with the key requirements and tools for successful vaccine development through informed guidance delivered by a top panel of speakers.

Featured Speakers:

• Steve Doberstein, Senior Vice President and Chief Scientific Officer, Nektar
• Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, MSD
• Fatema Legrand, Senior Clinical Scientist, Genentech
• David Giljohann, CEO, Exicure
• Steve Doberstein, Senior Vice President and Chief Scientific Officer, Nektar
• Agnete Fredriksen, Chief Scientific Officer, Vaccibody
• Mads Hald Andersen, Professor and Vice-Director, Centre for Cancer Immune Therapy, Copenhagen University Hospital; Founder, IO Biotech
• Rose-Ann Padua, Research Director, INSERM
• Zahra Jawad, Group Leader in Discovery Technology, Agenus

Exclusive highlights in 2017:

• Exploring personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development
• Maximising the therapeutic potential of cancer vaccines in combination with immune checkpoint inhibitors
• In depth case study examples of peptide, DNA, neoantigen and MHC based vaccine development
• Assessing the use of preclinical data for cancer vaccines

Cancer Vaccines 2017 is sponsored by Northwest Biotherapeutics
phone +44 (0) 207 827 6012
email kwilliams@smi-online.co.uk
web bit.ly/2rAmHA3
email Copthorne Tara Hotel, London
 
Print this page
Send to a friend
   
spacer
Industry Events

10th Annual Pre-Filled Syringes Europe 2018

17-18 January 2018, Copthorne Tara Hotel, Kensington, London UK

Join the calendar event highlight for the medical device industry at Europe's leading 10th annual conference and exhibition on Pre-Filled Syringes when it returns to Central London on 17th and 18th January 2018. Pre-Filled Syringes Europe will once again provide a perfect platform to discuss new advancements and showcase the latest innovations to keep you at the forefront of a dynamic and booming market.
More info >>

Banner of OCT Medical Devices Europe 2018_events_95 on Samedan

White Papers

Case Study: Amber™, featuring Pushclick Technology

SHL Group

The Amber™ Auto Injector is a single-dose, disposable auto injector with a unique patient-centric industrial design. This device features Pushclick™ technology, which enables it to be activated by simply pushing against the injection site, a total of only 2 simple steps. The unique ergonomic industrial design of the device provides various grip options when removing the cap and when performing the injection. Safety features and essential audible, visual and tactile feedback mechanisms are also integrated into the device.
More info >>


News and Press Releases

Charles River Announces Success of Integrated Discovery Project with ENYO Pharma

Wilmington, Mass and Lyon, France, Nov. 28, 2017 - Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement